Macrocyclic Factor VIIa Inhibitors for Anticoagulant Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticoagulants for thromboembolic disorders, such as warfarin, have a narrow therapeutic index, slow onset of action, and require monitoring, limiting their effectiveness and safety for wide-range prevention and treatment.
Innovation Solution
Development of novel macrocycles and their analogues as selective inhibitors of serine protease coagulation factor VIIa, which can be administered to prevent or treat thromboembolic disorders by inhibiting the coagulation cascade.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If warfarin is used as an anticoagulant, then thromboembolic disorders can be treated, but the therapeutic index is narrow and monitoring is required
Solution Approach 1:
The patent develops novel macrocyclic compounds with modified chemical structures that selectively inhibit factor VIIa. By changing the molecular parameters and binding characteristics of the anticoagulant, the therapeutic window is widened and the need for intensive monitoring is reduced, directly addressing the limitations of warfarin
Solution Approach 2:
The invention targets and isolates factor VIIa as a specific therapeutic target within the coagulation cascade. By extracting and inhibiting only this specific enzyme rather than affecting multiple coagulation factors broadly, the patent achieves more selective anticoagulation with improved safety margins and reduced monitoring requirements
2Reliability
If warfarin is used as an anticoagulant, then thromboembolic disorders can be treated, but the onset of action is slow
Solution Approach 1:
The macrocyclic compounds are designed to bind directly and immediately to factor VIIa, preventing its activation or catalytic activity from the outset. This preliminary inhibition of the specific enzyme eliminates the delay associated with warfarin's mechanism of inhibiting vitamin K-dependent factor synthesis, which takes time to deplete existing factors
3Reliability
If warfarin is used as an anticoagulant, then thromboembolic disorders can be treated, but dietary and drug interactions are numerous
Solution Approach 1:
The patent extracts and targets only factor VIIa as the specific therapeutic target, leaving other coagulation factors and metabolic pathways unaffected. This selective mechanism eliminates the numerous dietary and drug interactions that occur with warfarin, which affects multiple vitamin K-dependent factors and is sensitive to cytochrome P450 metabolism
Solution Approach 2:
The macrocyclic compounds act as selective intermediaries that specifically bind to and inhibit factor VIIa without interfering with other coagulation factors or metabolic enzymes. This intermediary action at a single targeted site reduces polypharmacy interactions and dietary restrictions compared to warfarin's broad mechanism
Data Source
AI summary
The present invention relates generally to novel macrocycles of Formula (I):or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, C, D, L, M, W, Z1, Z2, Z3, Z4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.